TELA Bio (TELA Bio) Total Inventories : $13.16 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TELA Bio Total Inventories?

TELA Bio's total inventories for the quarter that ended in Dec. 2023 was $13.16 Mil. TELA Bio's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $13.74 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. TELA Bio's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.06.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. TELA Bio's Days Inventory for the three months ended in Dec. 2023 was 233.35.

Inventory Turnover measures how fast the company turns over its inventory within a year. TELA Bio's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.39.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. TELA Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.81.

TELA Bio Total Inventories Historical Data

The historical data trend for TELA Bio's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Total Inventories Chart

TELA Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

4.60

3.91

7.66

11.79

13.16

TELA Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															11.79	15.11	14.10	14.32	13.16

TELA Bio Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

TELA Bio (NAS:TELA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

TELA Bio's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(46.729	+	0.75 * 9.737	+	0.5 * 13.162	-	59.167
-	0	-	0)	/	24.4947
=	0.06

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

TELA Bio's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	13.7425	/	5.374	*	365 / 4
	=	233.35

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

TELA Bio's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	5.374	/	13.7425
	=	0.39

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

TELA Bio's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	13.7425	/	16.998
	=	0.81

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

TELA Bio Total Inventories Related Terms

Thank you for viewing the detailed overview of TELA Bio's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

TELA Bio (TELA Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355

Website

https://www.telabio.com

TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

Executives

Gregory A. Firestone	officer: Chief Business Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca	officer: COO and CFO	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish	director, officer: Chief Executive Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p.	other: See footnotes 1 and 2	280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp	10 percent owner	QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p.	10 percent owner	CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran	director	0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess	director	2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans	director	1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355